Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.37 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2374046 | 1.00 | TRPM8 (0.37) | TRPM8NOS3NOS1NOS2TRPV1 | |
| SCHEMBL2373320 | 0.92 | NOS3 (0.42) | TRPM8NOS3NOS1NOS2TRPV1 | |
| SCHEMBL2373317 | 0.92 | NOS3 (0.42) | TRPM8NOS3NOS1NOS2TRPV1 | |
| SCHEMBL2376461 | 0.91 | PPARD (0.38) | NOS3NOS1NOS2PPARGPPARD | |
| SCHEMBL2376457 | 0.91 | PPARD (0.38) | NOS3NOS1NOS2PPARGPPARD | |
| SCHEMBL1124512 | 0.88 | TRPV1 (0.42) | TRPM8NOS3NOS1NOS2TRPV1 | |
| SCHEMBL1124509 | 0.88 | TRPV1 (0.42) | TRPM8NOS3NOS1NOS2TRPV1 | |
| SCHEMBL1124510 | 0.88 | TRPV1 (0.42) | TRPM8NOS3NOS1NOS2TRPV1 | |
| SCHEMBL2374005 | 0.87 | ESR1 (0.37) | TRPM8NOS3NOS1NOS2TRPV1 | |
| SCHEMBL2374011 | 0.87 | ESR1 (0.37) | TRPM8NOS3NOS1NOS2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | TRPM8 2184/4885NOS3 783/4885NOS1 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.